Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a phase 2a, multinational, multicenter clinical trial to evaluate the safety, tolerability, and pharmacokinetics of OMN6 in patients with hospital-acquired bacterial pneumonia HABP or ventilator-associated bacterial pneumonia VABP caused by Acinetobacter baumannii complex ABC. This study uses a double-blind, randomized, placebo-controlled design to identify safe doses and understand how OMN6 behaves in the body. Participants receive either OMN6 or a placebo alongside standard antibiotic treatment with meropenem and colistin. OMN6 is given as three 3-hour intravenous infusions in one day at doses of 50 mg, 100 mg, or 150 mg three times daily, while background antibiotic therapy continues for 7 to 14 days. The study compares OMN6 plus antibiotics to placebo plus antibiotics in a sequential randomized manner. During the study, participants will be monitored for safety outcomes over 28 days, including adverse effects and tolerance. Pharmacokinetic measures such as maximum concentration Cmax, time to maximum concentration Tmax, area under the curve AUC, and half-life t12 of OMN6 will be assessed within one day. The trial runs from May 2026 to March 2027, with participants undergoing treatment and follow-up evaluations to gather these data.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of once-weekly Somatrogon compared to daily Growth Hormone Genotropin for treating children born Small for Gestational Age SGA or with Idiopathic Short Stature ISS. This randomized, open-label study involves pre-pubertal children who have not previously received growth hormone treatment. The study is planned to last 12 months, including a screening period of up to 30 days, and aims to measure growth outcomes in these children. The study includes two groups one with 140 children with SGA and another with 114 children with ISS. Both groups will be randomly assigned to receive either Somatrogon once weekly via a subcutaneous disposable prefilled pen or Genotropin daily subcutaneous injections using commercial growth hormone delivery devices. Treatment will continue for 12 months for all participants. Participants will be involved in regular visits to assess growth through measurements such as annual height velocity, height standard deviation scores, bone maturation, and levels of Insulin-like Growth Factor-1 IGF-1. Quality of life related to health will also be evaluated before and after treatment. Monitoring includes laboratory tests and maintaining stable hormone levels. The total participation duration includes the screening and 12 months of treatment, with assessments at multiple time points throughout the study.
Actively Recruiting
Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to the standard care for hospitalized adult patients with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, and double-blind trial aims to compare trimodulin plus standard care against placebo plus standard care. The study also includes assessments of trimodulins detailed pharmacokinetic and pharmacodynamic properties. Participants are randomly assigned in a 11 ratio to receive either trimodulin or a placebo, both given intravenously once daily for five consecutive days alongside standard care. Following treatment, participants enter a follow-up phase lasting up to 23 days, with an end-of-follow-up visit or phone call on day 29. For those still hospitalized after day 29, extended follow-up continues until discharge or day 90, and a closing visit or call is conducted around day 91. During the study, participants will undergo multiple assessments including evaluation of mortality rates up to 28 and 90 days, clinical cure rates, organ failure scores, ventilator use, oxygen supply, ICU and hospital stays, readmission rates, adverse events, and changes in vital signs and laboratory parameters. Safety monitoring includes electrocardiograms and tracking of adverse events throughout the treatment and follow-up periods. The total participation duration can extend up to approximately three months depending on hospital discharge timing.